Uncategorized

NEW YORK, August 15, 2024 – Inc. revealed today that AlignRx ranks No. 1411 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Microsoft, Meta, Chobani, Under Armour, […]

As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence significant decisions that will impact healthcare spending. With some groups spending millions for diabetic drugs alone, it’s critical to understand the full spectrum of medications available, including newer players like

Traditional drug pipelines are now increasingly dominated by specialty drugs, many of which carry a six-figure annual per patient cost. This shift poses a significant financial challenge for health plans.

Buffalo Business First has named AlignRx as a finalist for its 2024 Best Places to Work awards in the category for companies with 10-24 employees. The results are based on an employee engagement survey that measures six key categories — communication, employee needs, manager effectiveness, personal engagement, team dynamic and trust in leadership. Winners are

CVS Formulary Change – What You Need to Know  CVS Caremark has announced the removal of Humira from some of their formularies starting the second quarter of 2024. The transition to biosimilar alternatives, which are part of the covered formulary, is planned.   Key Points of the Announcement  Impact Period: Starting April 1, 2024  Affected Parties:

Read the full article by AlignRx COO Greg Sanderson on Employee Benefit News.  Drug pricing is typically the main factor brokers and employer groups consider when evaluating PBMs. It makes sense. In a highly complex marketplace, their primary focus is getting their members’ prescriptions filled for the lowest price.   But projecting – and ultimately lowering

BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry. Kevin Kobielski, president & CEO of AlignRx was recognized in the Leadership category.  One of only nine individuals awarded in this category this year, Kevin is featured in the October 2023 issue

Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment — its independent, entrepreneurial businesses.  AlignRx partners with benefit consultants, employer groups, TPAs